BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BTLA inhibits T/B cell activation and the secretion of cytokines11”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with findings from previous studies11,42, and also activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells.”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“BTLA is the essential co‐signaling immune checkpoint protein with bidirectional functions [331].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [331]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“, and Y282 is similar to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1 (ref”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Chambers, C.A. et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28, 3137–3143 (1998). · doi:10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-x
- Bachmann, M.F. et al. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur. J. Immunol. 31, 450–458 (2001). · DOI · Paper page
Cited by
Items 101–200 of 894
Distinct Roles of Dendritic Cells and B Cells in Va14Ja18 Natural T Cell Activation In Vivo
Bezbradica, J. S., Stanic, A. K., Matsuki, N., Bour-Jordan, H., Bluestone, J. A., Thomas, J. W., Unutmaz, D., Van Kaer, L., & Joyce, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4696 · Cited by 158
“Therefore, we predict that either BTLA, a recently discovered member of the T and B cell-specific inhibitory receptor family (61), or a novel iNKT cell-specific inhibitory receptor, whose ligand(s) is specifically expressed by B cells, relays the negative signals to iNKT lymphocytes.”
BackgroundRoles of BTLA in Immunity and Immune Disorders
Ning, Z., Liu, K., & Xiong, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654960 · Cited by 157
“Mice with BTLA deficiency exhibit increased antigen-specific IgG responses and are sensitive to experimental autoimmune encephalomyelitis (EAE) (4, 78).”
BackgroundInfluentialHVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation
del Rio, M. L., Lucas, C. L., Buhler, L., Rayat, G., & Rodriguez-Barbosa, J. I. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0809590 · Cited by 157
“BTLA BTLA KO Spontaneous autoimmune hepatitis Increased susceptibility [63] BTLA KO EAE Increased susceptibility [14] BTLA KO Heart allograft class 1 MHC-mismatched 3 BTLA KO Decreased survival [69]”
BackgroundNot All Immune Checkpoints Are Created Equal
De Sousa Linhares, A., Leitner, J., Grabmeier-Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 148
“Engagement of BTLA was reported to lead to the recruitment of the SH2-domain containing phosphatases SHP-1 and SHP-2, which subsequently mediate the inhibitory effects of this receptor (40, 41).”
BackgroundImmune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 172
Cheung, T. C., Oborne, L. M., Steinberg, M. W., Macauley, M. G., Fukuyama, S., Sanjo, H., D'Souza, C., Norris, P. S., Pfeffer, K., Murphy, K. M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902490 · Cited by 153
“By contrast, HVEM engagement of BTLA and CD160 activates inhibitory signaling in lymphoid cells (2, 5, 10) through recruitment of SHP-1 and SHP-2 phosphatases, which attenuate tyrosine kinases activated by TCR Ag recognition (2, 11, 12).”
BackgroundSelf-citationJones, A., Bourque, J., Kuehm, L., Opejin, A., Teague, R. M., Gross, C., & Hawiger, D. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.008 · Cited by 154
“, 2007), and Btla / (Watanabe et al., 2003) mice were previously described and are available from the Jackson Laboratory.”
BackgroundMethodInfluentialCelis-Gutierrez, J., Blattmann, P., Zhai, Y., Jarmuzynski, N., Ruminski, K., Grégoire, C., Ounoughene, Y., Fiore, F., Aebersold, R., Roncagalli, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.041 · Cited by 154
“BTLA recognizes the herpes virus entry mediator (HVEM), a member of the tumor necrosis factor receptor superfamily, and BTLA-deficient T cells show increased antigen responsiveness (Krieg et al., 2007; Watanabe et al., 2003).”
BackgroundMethodBiomarkers for Sepsis: What is and What Might Be?
Girard, B., Ayala, A., & Lomas‐Neira, J. (2015) · Biomarker Insights · doi:10.4137/bmi.s29519 · Cited by 171
Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma
Tirapu, I., Huarte, E., Guiducci, C., Arina, A., Zaratiegui, M., Murillo, O., Gonzalez, A., Berasain, C., Berraondo, P., Fortes, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1681 · Cited by 141
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 141
Self-citationTCR signal strength controls the differentiation of CD4 + effector and memory T cells
Snook, J. P., Kim, C., & Williams, M. A. (2018) · Science Immunology · doi:10.1126/sciimmunol.aas9103 · Cited by 139
A crucial role for HVEM and BTLA in preventing intestinal inflammation
Steinberg, M. W., Turovskaya, O., Shaikh, R. B., Kim, G., McCole, D. F., Pfeffer, K., Murphy, K. M., Ware, C. F., & Kronenberg, M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071160 · Cited by 137
Self-citationB and T lymphocyte attenuator regulates CD8+ T cell–intrinsic homeostasis and memory cell generation
Krieg, C., Boyman, O., Fu, Y., & Kaye, J. (2007) · Nature Immunology · doi:10.1038/ni1418 · Cited by 148
“The murine Btla gene has been independently identified in screens for genes upregulated in thymocytes undergoing positive selection and T helper type 1 (T H 1) cell”
BackgroundThe B7/CD28 costimulatory family in autoimmunity
Keir, M. E., & Sharpe, A. H. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00242.x · Cited by 136
“HVEM is the unique ligand for BTLA the identities of the receptors that bind B7-H3 and B7-H4 are currently unknown.”
BackgroundInfluentialPan, Z., Ye, F., Wu, X., An, H., & Wu, J. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.02.13 · Cited by 141
Arnett, H. A., Escobar, S. S., Gonzalez-Suarez, E., Budelsky, A. L., Steffen, L. A., Boiani, N., Zhang, M., Siu, G., Brewer, A. W., & Viney, J. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1523 · Cited by 139
“Mice lacking either BTLA or PD-1 are predisposed to develop autoimmune phenotypes with signs of progressive arthritis and glomerulonephritis, suggesting their roles in the inhibition of inflammatory responses and in maintaining peripheral tolerance (11, 41), therefore it is possible that mice lacking BTNL2 might be mo…”
BackgroundGamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138
“Binding with their respective immune checkpoint receptors (ICRs) leads to phosphorylation of the immune receptor tyrosine-based inhibition motif (ITIM)/immune receptor tyrosine-based switch motif (ITSM), leading to the activation of Scr homology region 2 domaincontaining phosphatase (SHP-1/2), triggering a series of d…”
BackgroundKLRG1 binds cadherins and preferentially associates with SHIP-1
Tessmer, M. S., Fugere, C., Stevenaert, F., Naidenko, O. V., Chong, H. J., Leclercq, G., & Brossay, L. (2007) · International Immunology · doi:10.1093/intimm/dxm004 · Cited by 131
T‐cell growth, cell surface organization, and the galectin–glycoprotein lattice
Grigorian, A., Torossian, S., & Demetriou, M. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00796.x · Cited by 133
“Programmed death-1 receptor (PD-1) and B- and T-lymphocyte attenuator (BTLA) are induced in activated T cells, promote growth arrest, and inhibit autoimmunity (90, 91).”
BackgroundT Lymphocytes and Autoimmunity
Khan, U., & Ghazanfar, H. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.008 · Cited by 156
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
DC-HIL is a negative regulator of T lymphocyte activation
Chung, J.-S., Sato, K., Dougherty, I. I., Cruz, P. D., & Ariizumi, K. (2007) · Blood · doi:10.1182/blood-2006-11-053769 · Cited by 132
“BTLA-knockout mice do not exhibit developmental T or B cell defects, but their lymphocytes have heightened responses to anti-CD3 Ab and to antiIgM Ab;(8) these mice are also prone to developing EAE.(8) In the case of the Tim-3 pathway, its blockade by mAb, Fc-fused soluble receptor, or gene disruption leads to exacerb…”
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xu, X., Hou, B., Fulzele, A., Masubuchi, T., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., et al. (2020) · Journal of Cell Biology · doi:10.1083/jcb.201905085 · Cited by 130
Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 145
SHP-1 phosphatase activity counteracts increased T cell receptor affinity
Hebeisen, M., Baitsch, L., Presotto, D., Baumgaertner, P., Romero, P., Michielin, O., Speiser, D. E., & Rufer, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65325 · Cited by 123
“In contrast, BTLA, known to inhibit T cell function (17), was expressed at the highest levels in wtc51m-expressing T cells (Figure 4A).”
B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation
Barwick, B. G., Scharer, C. D., Martinez, R. J., Price, M. J., Wein, A. N., Haines, R. R., Bally, A. P. R., Kohlmeier, J. E., & Boss, J. M. (2018) · Nature Communications · doi:10.1038/s41467-018-04234-4 · Cited by 118
The nature of activatory and tolerogenic dendritic cell-derived signal II
Bakdash, G., Sittig, S. P., van Dijk, T., Figdor, C. G., & de Vries, I. J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00053 · Cited by 135
“In an EAE model, BTLA-deficient mice displayed increased severity and persistence of disease when compared with wild type controls (Watanabe et al., 2003).”
T-Cell Costimulatory Pathways in Allograft Rejection and Tolerance
Clarkson, M. R., & Sayegh, M. H. (2005) · Transplantation · doi:10.1097/01.tp.0000168432.60022.99 · Cited by 139
Bian, B., Fanale, D., Dusetti, N., Roque, J., Pastor, S., Chretien, A.-S., Incorvaia, L., Russo, A., Olive, D., & Iovanna, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1561120 · Cited by 126
“The B and T lymphocyte attenuator (BTLA/CD272) belongs to the CD28 Ig superfamily and is a type I transmembrane cosignaling receptor.(27) This molecule is expressed at high level in resting immune cells including T-cells.”
BackgroundHe, Y.-F., Zhang, G.-M., Wang, X.-H., Zhang, H., Yuan, Y., Li, D., & Feng, Z.-H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4919 · Cited by 128
“In fact, there are other negative costimulatory receptors on T cells except for PD-1, such as CTLA-4 and B and T lymphocyte attenuator, a newly discovered inhibitory receptor with similarities to CTLA-4 and PD-1 (46).”
BackgroundReview of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Alturki, N. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134301 · Cited by 135
“However, skin, hepatic, and pulmonary-related irAEs are more frequent in the case of anti-PD1 antibody administration than anti-CTLA4 antibodies, it is the opposite for thyroid and lower digestive tract irAEs, such as colitis [43].”
BackgroundFrontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells
Compte, E., Pontarotti, P., Collette, Y., Lopez, M., & Olive, D. (2004) · European Journal of Immunology · doi:10.1002/eji.200425227 · Cited by 132
Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity
Ramsay, A. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12380 · Cited by 140
The emerging role of the CTLA-4 gene in autoimmune endocrinopathies
Vaidya, B., & Pearce, S. H. S. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500619 · Cited by 139
Tao, R., Wang, L., Han, R., Wang, T., Ye, Q., Honjo, T., Murphy, T. L., Murphy, K. M., & Hancock, W. W. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5774 · Cited by 120
“B7x (B7H4, B7S1) as a BTLA ligand (10, 14, 15), recent work”
BackgroundResultInfluentialSelf-citationB and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK
Vendel, A. C., Calemine-Fenaux, J., Izrael-Tomasevic, A., Chauhan, V., Arnott, D., & Eaton, D. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1509 · Cited by 118
“BTLA recruits the protein tyrosine phosphatase SHP1 in T and B cells, but beyond this, it is unclear how BTLA activity leads to suppressed lymphocyte activation (6, 9, 11).”
BackgroundInfluentialFunctional Dichotomy between OX40 and 4-1BB in Modulating Effector CD8 T Cell Responses
Lee, S., Park, Y., Song, A., Cheroutre, H., Kwon, B. S., & Croft, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4464 · Cited by 127
Wang, S., & Chen, L. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.03.007 · Cited by 133
Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways
Ware, C. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00629.x · Cited by 125
“Two major functional groups of cell surface cosignaling regulators are recognized, those containing an immunoglobulin (Ig)-like fold in their ecto domains, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) (1), CD28 (2), programmed death 1 (PD1) (3), and B–T lymphocyte attenuator (BTLA) (4, 5).”
BackgroundOya, Y., Watanabe, N., Owada, T., Oki, M., Hirose, K., Suto, A., Kagami, S., Nakajima, H., Kishimoto, T., Iwamoto, I., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23674 · Cited by 114
“BTLA / mice were established on a 129SvEv background as described previously (8).”
BackgroundMethodResultInfluentialSelf-citationMintz, M. A., Felce, J. H., Chou, M. Y., Mayya, V., Xu, Y., Shui, J.-W., An, J., Li, Z., Marson, A., Okada, T., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.022 · Cited by 110
“BTLA contains ITIM (immunoreceptor tyrosine-based inhibition) motifs in its cytoplasmic domain and can recruit both SH2-domain-containing tyrosine phosphatases SHP1 and SHP2, but not SHIP or SAP (Chemnitz et al., 2004; Gavrieli et al., 2003; Steinberg et al., 2011; Watanabe et al., 2003).”
BackgroundMethodInfluentialFive Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation
Ribeiro, S. T., Ribot, J. C., & Silva-Santos, B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00015 · Cited by 116
Immunotherapy in the treatment of non-small cell lung cancer
Sundar, R., Soong, R., Cho, B. C., Brahmer, J. R., & Soo, R. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.005 · Cited by 123
Noncoding RNA s and immune checkpoints—clinical implications as cancer therapeutics
Smolle, M. A., Calin, H. N., Pichler, M., & Calin, G. A. (2017) · The FEBS Journal · doi:10.1111/febs.14030 · Cited by 113
Syndecan-4 Mediates the Coinhibitory Function of DC-HIL on T Cell Activation
Chung, J.-S., Dougherty, I., Cruz, P. D., & Ariizumi, K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5778 · Cited by 114
“B and T lymphocyte attenuator, CTLA-4, and PD-1 possess a typical ITIM, an ITIM-like motif, and an immunoreceptor tyrosine-based switch motif, respectively (37), that can activate the tyrosine phosphatases, SHP-1 and SHP-2, responsible for mediating negative T cell effector function (11, 38).”
BackgroundPD-1/PD-L pathway and autoimmunity
Okazaki, T., & Wang, J. (2005) · Autoimmunity · doi:10.1080/08916930500124072 · Cited by 135
Molecular signatures of T-cell inhibition in HIV-1 infection
Larsson, M., Shankar, E. M., Che, K. F., Saeidi, A., Ellegård, R., Barathan, M., Velu, V., & Kamarulzaman, A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-31 · Cited by 126
“Engagement of BTLA on T cells with its ligand HVEM inhibits effector CD4 T-cell functions [66,69,70].”
BackgroundTumor Necrosis Factor Superfamily in Innate Immunity and Inflammation
Šedý, J., Bekiaris, V., & Ware, C. F. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016279 · Cited by 109
“HVEM activates BTLA resulting in phosphorylation of its cytoplasmic domain and recruitment of the Src homology-2 (SH2) containing phosphatase (SHP)-1 and 2 to its carboxy-terminal motif (Watanabe et al. 2003; Šedý et al. 2005).”
BackgroundInfluentialSelf-citationRegulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling
Shui, J.-W., Steinberg, M. W., & Kronenberg, M. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0910528 · Cited by 109
“protein [33, 34].”
PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis
Ding, H., Wu, X., & Gao, W. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.01.005 · Cited by 119
Robson, M. I., de las Heras, J. I., Czapiewski, R., Sivakumar, A., Kerr, A. R. W., & Schirmer, E. C. (2017) · Genome Research · doi:10.1101/gr.212308.116 · Cited by 107
Gertner-Dardenne, J., Fauriat, C., Orlanducci, F., Thibult, M.-L., Pastor, S., Fitzgibbon, J., Bouabdallah, R., Xerri, L., & Olive, D. (2013) · Blood · doi:10.1182/blood-2012-11-464685 · Cited by 100
“B- and T-lymphocyte attenuator (BTLA), a recently described member of the CD28:B7 family structurally related to CTLA-4 and PD-1, is expressed by most lymphocytes.(18) Its ligand, herpesvirus entry mediator (HVEM), is a member of the tumor necrosis factor (TNF) receptor superfamily expressed by T, B, and NK cells; den…”
BackgroundRegulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity
Stanford, S. M., Rapini, N., & Bottini, N. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03591.x · Cited by 102
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Khan, M. S. I., Arooj, S., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651634 · Cited by 106
Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization
Xu, Z., Guo, C., Ye, Q., Shi, Y., Sun, Y., Zhang, J., Huang, J., Huang, Y., Zeng, C., Zhang, X. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26697-8 · Cited by 105
The regulation of lymphocyte activation by inhibitory receptors
Leibson, P. J. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.03.006 · Cited by 110
Muenst, S., Soysal, S. D., Tzankov, A., & Hoeller, S. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.980235 · Cited by 97
“Co-stimulatory receptors such as CD28 promote T cell activation, whereas co-inhibitory receptors such as programmed death-1 (PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4) or B and T lymphocyte attenuator -- referred to as ‘immune checkpoint molecules’ -- inhibit T cell function, thus preventing inappropriately dire…”
BackgroundPathogenic CD8+ T cells in experimental cerebral malaria
Howland, S. W., Claser, C., Poh, C. M., Gun, S. Y., & Rénia, L. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0476-6 · Cited by 112
Šedý, J. R., Bjordahl, R. L., Bekiaris, V., Macauley, M. G., Ware, B. C., Norris, P. S., Lurain, N. S., Benedict, C. A., & Ware, C. F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300894 · Cited by 100
“EL4 cells were transduced with human BTLA-IRES-GFP or human CD160 (Open Biosystems, Huntsville, AL) cloned into IRES-GFP retroviral plasmid by PCR amplification (hCD1605BglII: 59-AGTCAGATCTGCGTGCAGGATGCTGTTG-39; hCD1603XhoI: 59-AGTCCTCGAGGGCTTACAAAGCTTGAAGGG-39) (33).”
MethodCellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion
Verdon, D. J., Mulazzani, M., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197357 · Cited by 98
“B- and T- cell lymphocyte attenuator (BTLA), discovered in 2003 [220], is another transmembrane member of the Ig-superfamily, expressed after T cell activation.”
BackgroundmiRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
Martino, M. T. D., Riillo, C., Scionti, F., Grillone, K., Polerà, N., Caracciolo, D., Arbitrio, M., Tagliaferri, P., & Tassone, P. (2021) · Cancers · doi:10.3390/cancers13071587 · Cited by 102
Shubin, N. J., Monaghan, S. F., Heffernan, D. S., Chung, C.-S., & Ayala, A. (2013) · Critical Care · doi:10.1186/cc13131 · Cited by 96
“Co-inhibitory receptors, including programmed death receptor-1 (PD-1), cytotoxic T-lymphocyte antigen-4 (CTLA-4), and BTLA, have also recently gained traction as effective (in the case of anti-CTLA-4; ipilimumab) or potential therapeutic targets in a number of disease states [18,21-23].”
BackgroundResultInfluentialBolandi, N., Derakhshani, A., Hemmat, N., Baghbanzadeh, A., Asadzadeh, Z., Nour, M. A., Brunetti, O., Bernardini, R., Silvestris, N., & Baradaran, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910719 · Cited by 104
Costimulation, Coinhibition and Cancer
Inman, B. A., Frigola, X., Dong, H., & Kwon, E. D. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780006878 · Cited by 112
“B and T lymphocyte attenuator) is a receptor found on activated B cells and T cells that has many structural and functional similarities to PD-1 [67].”
BackgroundShubin, N. J., Chung, C. S., Heffernan, D. S., Irwin, L. R., Monaghan, S. F., & Ayala, A. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.1211641 · Cited by 95
“BTLA has been shown to inhibit CD4 T cell proliferation, polarization into Th1 cells, as well as inducing CD4 T cell apoptosis [11, 34].”
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
Chen, Y., Lin, H.-W., Chien, C. L., Lai, Y.-L., Sun, W., Chen, C., & Cheng, W. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0744-4 · Cited by 103
“BTLA includes two immunoreceptor tyrosine-based inhibitory motifs in its cytoplasmic region [9] and can be identified on various immunocytes such as T and B lymphocytes, macrophages, dendritic cells, and nature killer (NK) cells [10].”
BackgroundInfluentialCostimulatory receptors in jawed vertebrates: Conserved CD28, odd CTLA4 and multiple BTLAs
BERNARD, D., Hansen, J. A., DuPasquier, L., Lefranc, M., Benmansour, A., & Boudinot, P. (2006) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2006.06.003 · Cited by 100
“The last receptor to be considered as a member of the CD28 family was identified as ‘‘B and T lymphocyte attenuator’’ (BTLA) [8], and was initially described as a ligand for an additional B7-related molecule, B7x.”
BackgroundThe Inhibitory Receptor BTLA Controls γδ T Cell Homeostasis and Inflammatory Responses
Bekiaris, V., Šedý, J. R., Macauley, M. G., Rhode-Kurnow, A., & Ware, C. F. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.017 · Cited by 95
“Our findings using a gd T cell-dependent model of inflammatory dermatitis contribute to previous data that BTLA-deficient animals are prone to the induction of autoimmune disease that in wild-type animals results in subclinical outcomes (Watanabe et al., 2003).”
BackgroundResultInfluentialSelf-citationNegative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 101
“BTLA (CD272) B and T lymphocyte attenuator BTLA (CD272) is an Ig-domain-containing transmembrane glycoprotein (Watanabe et al., 2003) that belongs to the CD28 IgSF.”
BackgroundInfluentialTao, R., Wang, L., Murphy, K. M., Fraser, C. C., & Hancock, W. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6649 · Cited by 92
“The most recently recognized CD28 homolog, B and T lymphocyte attenuator (BTLA, CD272) (5), is unusual in that it interacts with the TNFR superfamily member, herpesvirus entry mediator (HVEM, TNFRSF14) (6).”
BackgroundSelf-citationReal-Time Imaging of Notch Activation with a Luciferase Complementation-Based Reporter
Ilagan, M. X. G., Lim, S., Fulbright, M., Piwnica-Worms, D., & Kopan, R. (2011) · Science Signaling · doi:10.1126/scisignal.2001656 · Cited by 95
M’Hidi, H., Thibult, M., Chetaille, B., Gondois‐Rey, F., Bouadallah, R., Nicollas, R., Olive, D., & Xerri, L. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcpphkgyyggl39c · Cited by 97
Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy
Horton, J. D., Knochelmann, H. M., Day, T. A., Paulos, C. M., & Neskey, D. M. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.007 · Cited by 103
“(B) Upregulation of inhibitory checkpoint molecules such as PD-1 and CTLA-4 impair memory T cell priming and promote exhaustion in the context of chronic stimulation.”
BackgroundInfluentialDeppong, C., Juehne, T. I., Hurchla, M., Friend, L. D., Shah, D. D., Rose, C. M., Bricker, T. L., Shornick, L. P., Crouch, E. C., Murphy, T. L., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.3909 · Cited by 89
“BTLA-deficient mice (strain Btla) in the C57BL/6 background were generated as described previously (3).”
BackgroundMethodSelf-citationDurable SARS-CoV-2 B cell immunity after mild or severe disease
Ogega, C. O., Skinner, N., Blair, P. W., Park, H.-S., Littlefield, K. E., Ganesan, A., Dhakal, S., Ladiwala, P., Antar, A. A. R., Ray, S. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145516 · Cited by 99
Functional Analysis of B and T Lymphocyte Attenuator Engagement on CD4+ and CD8+ T Cells
Krieg, C., Han, P., Stone, R., Goularte, O. D., & Kaye, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.6420 · Cited by 90
“Thus, BTLA engagement under the limiting conditions of costimulation or TCR activation that may occur in vivo may deliver an inhibitory signal.”
BackgroundMethodInfluentialBTLA: a new inhibitory receptor with a B7-like ligand
Carreno, B. M., & Collins, M. A. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.08.005 · Cited by 95
Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells
Otsuki, N., Yousuke, K., Hashiguchi, M., & Azuma, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.242 · Cited by 96
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., Granda‐Díaz, R., Martínez‐Pérez, A., Aguilar-García, C., Rodrigo, J. P., Garcia-Pedrero, J. M., & Gonzalez, S. R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01845-4 · Cited by 95
“…observations, in vitro studies revealed that BTLA deletion significantly enhanced T cell proliferation upon stimulation with anti-CD3 monoclonal antibodies (mAbs) or peptide-loaded antigen-presenting cells (APCs), while this effect was not observed in the BTLA wild-type (WT) counterparts [12, 20].”
BackgroundCostimulatory pathways in transplantation
Pilat, N., Sayegh, M. H., & Wekerle, T. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.04.002 · Cited by 93
Chemnitz, J. M., Lanfranco, A. R., Braunstein, I., & Riley, J. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6603 · Cited by 85
“This is in contrast to the 2-fold differences observed using cell line models (10).”
BackgroundMethodResultInfluentialMaasho, K., Masilamani, M., Valas, R. B., Basu, S., Coligan, J. E., & Borrego, F. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.01.004 · Cited by 92
Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA
Gavrieli, M., & Murphy, K. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.036 · Cited by 85
Self-citationCD63 as an Activation-Linked T Cell Costimulatory Element
Grabmeier‐Pfistershammer, K., Majdic, O., Stöckl, J., Zlabinger, G. J., Kirchberger, S., Steinberger, P., & Knapp, W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6000 · Cited by 99
Ho, P. P., & Steinman, L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524890113 · Cited by 85
“BTLA is another negative checkpoint regulator with expression limited to B cells, T cells, mature dendritic cells, and macrophages (32).”
BackgroundTumour escape: antitumour effectors too much of a good thing?
Pawelec, G. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0469-5 · Cited by 95
“Undoubtedly, yet more negative receptors remain to be discovered [160]; complete knowledge of all such possible interactions might be beneficial in manipulating responses in the desired direction.”
BackgroundKozela, E., Juknat, A., Gao, F., Kaushansky, N., Coppola, G., & Vogel, Z. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0603-x · Cited by 81
BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection
Yu, X., Zheng, Y., Mao, R., Su, Z., & Zhang, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00617 · Cited by 83
“Its protein structure is similar to those of CTLA-4 and PD-1 and includes an extracellular domain, transmembrane domain, and cytoplasmic domain (32).”
BackgroundDe Trez, C., Schneider, K., Potter, K., Droin, N., Fulton, J., Norris, P. S., Ha, S.-W., Fu, Y.-X., Murphy, T., Murphy, K. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.238 · Cited by 82
“Mice deficient in LT R / (42), LIGHT / (43), LT / (44), LT / LIGHT / (43), HVEM / (45), alymphoplasia (aly) (46), or BTLA / (47) were inbred in the C57Bl/6 background.”
BackgroundSelf-citationFann, M., Chiu, W. K., Wood, W. H., Levine, B. L., Becker, K. G., & Weng, N. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00262.x · Cited by 81
Breakdown in Peripheral Tolerance in Type 1 Diabetes in Mice and Humans
Jeker, L. T., Bour-Jordan, H., & Bluestone, J. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007807 · Cited by 95
“B- and T-lymphocyte attenuator (BTLA) is a negative regulator of T-cell activation that is predominantly expressed on recently activated T cells and differentiated Th1 cells (Watanabe et al. 2003).”
BackgroundFülöp, T., Larbi, A., Dupuis, G., & Pawelec, G. (2003) · Arthritis Res Ther · doi:10.1186/ar1019 · Cited by 81
“mice were completely resistant to RA [99].”
Hurchla, M. A., Sedy, J. R., & Murphy, K. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6073 · Cited by 81
“These results suggest that BTLA may act not only as an inhibitor as shown previously (1, 2, 4, 5) but, under some conditions, may participate in providing signals that promote the immune responses.”
BackgroundMethodInfluentialSelf-citationPan-Cancer Analysis of Ligand–Receptor Cross-talk in the Tumor Microenvironment
Ghoshdastider, U., Rohatgi, N., Naeini, M. M., Baruah, P., Revkov, E., Guo, Y. A., Rizzetto, S., Wong, A. M. L., Solai, S., Nguyen, T. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2352 · Cited by 94
“Interactions between BTLA ligands on immune cell and TNFRSF14, also known as herpesvirus entry mediator (HVEM), trigger inhibition of T-cell immune responses (43).”
BackgroundThe expression, function, and clinical relevance of B7 family members in cancer
Seliger, B., & Quandt, D. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1293-6 · Cited by 85
A cellular platform for the evaluation of immune checkpoint molecules
Jutz, S., Hennig, A., Paster, W., Asrak, Ö., Dijanovic, D., Kellner, F., Pickl, W. F., Huppa, J. B., Leitner, J. M., & Steinberger, P. (2017) · Oncotarget · doi:10.18632/oncotarget.17615 · Cited by 84
“Although the role of BTLA as coinhibitory receptor in B and T lymphocytes is well established [44, 45], it is currently not known which signaling motifs transduce inhibitory signals into T cells.”
BackgroundImmunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells
Bourque, J., & Hawiger, D. (2018) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018026790 · Cited by 82
Hickman, S. P., Yang, J., Thomas, R. M., Wells, A. D., & Turka, L. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2186 · Cited by 91
Self-citationGeneration and Characterization of B7-H4/B7S1/B7x-Deficient Mice
Suh, W.-K., Wang, S., Duncan, G. S., Miyazaki, Y., Cates, E., Walker, T., Gajewska, B. U., Deenick, E., Dawicki, W., Okada, H., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00755-06 · Cited by 77
“Since the unknown receptor(s) for B7-H4 is expressed at a high level in Th1 cells (26, 44, 48), we reasoned that the impact of B7-H4 deficiency would be most pronounced under Th1-polarizing conditions.”
BackgroundResultInfluential
Metadata
- Authors
- Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Perugia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Murphy, Kenneth M
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-06-08
- Volume
- 4
- Issue
- 7
- Pages
- 670-679
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2118705059
- Cited by
- 883
- References
- 52
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 38 · 2023: 38 · 2022: 38 · 2021: 59 · 2020: 56 · 2019: 49 · 2018: 35 · 2017: 29 · 2016: 31 · 2015: 36 · 2014: 34 · 2013: 41 · 2012: 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- BTLA, inhibitory receptors, T cell costimulation, CTLA-4, PD-1, SHP-1, SHP2, tyrosine phosphorylation, interleukin-2, T helper cell differentiation, B7 ligands, T cell proliferation, experimental autoimmune encephalomyelitis, antibody response
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, Encephalomyelitis, Autoimmune, Experimental, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, Proteins, Receptors, Immunologic, RNA, Messenger, T-Lymphocytes, Antigens, CD, Protein Tyrosine Phosphatases, B7-1 Antigen, Immunoconjugates, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.